ReviewDrugs & aging2009
Cerebrolysin: a review of its use in dementia.
Review in Drugs & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Cerebrolysin for vascular dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs · 2011Pooled it
- Conservative and newer drug treatment for degenerative cervical myelopathy.Journal of clinical orthopaedics and trauma · 2025Article
- Cerebral amyloid angiopathy: a narrative review.Frontiers in aging neuroscience · 2025Review
- Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex.Neurochemical research · 2024Article
- Mitigating Traumatic Brain Injury: A Narrative Review of Supplementation and Dietary Protocols.Nutrients · 2024Review
- Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence.Neurospine · 2024Article
- Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.Metabolic brain disease · 2023Article
- Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer's Disease Exacerbated by Concussive Head Injury.Advances in neurobiology · 2023Review
- Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation.European journal of medical research · 2022Article
- Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis.Cerebral circulation - cognition and behavior · 2021Article
- Effects of Cerebrolysin on Hippocampal Neuronal Death After Pilocarpine-Induced Seizure.Frontiers in neuroscience · 2020Article
- Cerebrolysin Ameliorates Focal Cerebral Ischemia Injury Through Neuroinflammatory InhibitionFrontiers in pharmacology · 2019Article
- Strategies targeting endogenous neurogenic cell response to improve recovery following traumatic brain injury.Brain research · 2016Review
- Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.Journal of experimental neuroscience · 2015Article
- Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.BMC neuroscience · 2014Article
- A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Frontiers in psychiatry · 2014Review
- Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.Neuropsychiatric disease and treatment · 2014Article
- Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.Journal of experimental pharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability. A large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global measures and cognition for all three treatment groups compared with baseline. Although not as extensively studied in patients with vascular dementia, Cerebrolysin has also shown beneficial effects on global measures and cognition in this patient population. Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event. Although further studies with Cerebrolysin, including longer term trials and further exploration of its use in combination with cholinesterase inhibitors, are needed to more clearly determine its place in the management of Alzheimer's disease and vascular dementia, available data suggest that Cerebrolysin is a useful addition to the treatment options available for dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.